GALT
Price:
$2.525
Market Cap:
$157.25M
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment ...[Read more]
Industry
Biotechnology
IPO Date
2002-09-04
Stock Exchange
NASDAQ
Ticker
GALT
According to Galectin Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.87. This represents a change of -3.07% compared to the average of 1.93 of the last 4 quarters.
The mean historical Current Ratio of Galectin Therapeutics Inc. over the last ten years is 7.70. The current 1.87 Current Ratio has changed 2.32% with respect to the historical average. Over the past ten years (40 quarters), GALT's Current Ratio was at its highest in in the September 2019 quarter at 41.51. The Current Ratio was at its lowest in in the December 2017 quarter at 1.29.
Average
7.70
Median
4.41
Minimum
1.29
Maximum
19.41
Discovering the peaks and valleys of Galectin Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 308.03%
Maximum Annual Current Ratio = 19.41
Minimum Annual Increase = -78.48%
Minimum Annual Current Ratio = 1.29
Year | Current Ratio | Change |
---|---|---|
2023 | 1.77 | 11.92% |
2022 | 1.58 | -65.88% |
2021 | 4.63 | -15.17% |
2020 | 5.46 | -68.08% |
2019 | 17.10 | 308.03% |
2018 | 4.19 | 225.61% |
2017 | 1.29 | -69.20% |
2016 | 4.18 | -78.48% |
2015 | 19.41 | 11.45% |
2014 | 17.42 | 305.15% |
The current Current Ratio of Galectin Therapeutics Inc. (GALT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.66
5-year avg
6.11
10-year avg
7.70
Galectin Therapeutics Inc.’s Current Ratio is less than Madrigal Pharmaceuticals, Inc. (5.98), less than Viking Therapeutics, Inc. (36.47), less than Sarepta Therapeutics, Inc. (3.90), less than Hepion Pharmaceuticals, Inc. (5.62), less than PTC Therapeutics, Inc. (2.23), less than Intercept Pharmaceuticals, Inc. (4.22), less than Terns Pharmaceuticals, Inc. (21.02), less than Akero Therapeutics, Inc. (24.89), less than Reata Pharmaceuticals, Inc. (3.21), less than DiaMedica Therapeutics Inc. (17.82), less than Milestone Pharmaceuticals Inc. (19.13), greater than Seres Therapeutics, Inc. (1.38), less than Inhibikase Therapeutics, Inc. (2.32), less than Oncolytics Biotech Inc. (4.99), less than 89bio, Inc. (13.92), less than Pliant Therapeutics, Inc. (14.47), less than Arcellx, Inc. (6.01), less than Stoke Therapeutics, Inc. (6.67),
Company | Current Ratio | Market cap |
---|---|---|
5.98 | $7.23B | |
36.47 | $7.04B | |
3.90 | $11.74B | |
5.62 | $3.68M | |
2.23 | $3.11B | |
4.22 | $794.69M | |
21.02 | $599.50M | |
24.89 | $2.23B | |
3.21 | $6.57B | |
17.82 | $189.37M | |
19.13 | $78.84M | |
1.38 | $137.42M | |
2.32 | $175.37M | |
4.99 | $87.76M | |
13.92 | $983.90M | |
14.47 | $881.01M | |
6.01 | $4.65B | |
6.67 | $689.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galectin Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Galectin Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Galectin Therapeutics Inc.'s Current Ratio?
How is the Current Ratio calculated for Galectin Therapeutics Inc. (GALT)?
What is the highest Current Ratio for Galectin Therapeutics Inc. (GALT)?
What is the 3-year average Current Ratio for Galectin Therapeutics Inc. (GALT)?
What is the 5-year average Current Ratio for Galectin Therapeutics Inc. (GALT)?
How does the current Current Ratio for Galectin Therapeutics Inc. (GALT) compare to its historical average?